NCT03909607View on ClinicalTrials.gov

Nebulized Sub-dissociative Dose Ketamine for Treating Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

October 30, 2020

Study Completion Date

June 30, 2021

Conditions
Pain
Interventions
DRUG

Ketamine 0.75 mg/kg

Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg

DRUG

Ketamine 1.0 mg/kg

Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg

DRUG

Ketamine 1.5 mg/kg

Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg

Trial Locations (1)

11219

Maimonides Medical Center, Brooklyn

All Listed Sponsors
lead

Antonios Likourezos

OTHER

NCT03909607 - Nebulized Sub-dissociative Dose Ketamine for Treating Pain | Biotech Hunter | Biotech Hunter